<DOC>
	<DOC>NCT01524341</DOC>
	<brief_summary>This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day</brief_summary>
	<brief_title>Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Vivax</mesh_term>
	<criteria>Male and female patients aged 20 to 60 years Presence of monoinfection of P. falciparum or P. vivax Weight between 40 kg to 90 kg Patients with signs and symptoms of severe/complicated malaria Mixed Plasmodium infection Presence of other serious or chronic clinical condition requiring hospitalization. Severe malnutrition Significant chronic medical conditions which in the opinion of the investigator preclude enrollment into the study Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Acute malaria</keyword>
	<keyword>KAE609</keyword>
</DOC>